TLX
HealthcareTelix Pharmaceuticals Limited · Biotechnology · $3B
What is Telix Pharmaceuticals Limited?
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in radiopharmaceuticals for cancer and rare diseases. Operating across Australia, the United States, Europe, and Japan, Telix bridges diagnostic imaging and targeted cancer therapy through nuclear medicine.
Telix develops and commercializes radiopharmaceuticals — medicines that use radioactive compounds to image or treat tumors at the cellular level. Its lead commercial product, Illuccix, targets prostate cancer imaging. Beyond diagnostics, the company is advancing a pipeline of therapeutic candidates designed to deliver radiation directly to cancer cells, covering prostate cancer, kidney cancer, brain cancer, and soft tissue sarcoma.
Founded in 2015 and headquartered in North Melbourne, Australia, Telix has grown rapidly from a development-stage company into a commercial radiopharmaceutical business.
- Illuccix — approved prostate cancer imaging agent
- TLX591 — radio antibody-drug conjugate for prostate cancer treatment
- TLX250-CDx — diagnostic and therapeutic candidate for kidney cancer
- TLX101 — investigational therapy for glioblastoma brain cancer
- TLX66-CDx — bone marrow conditioning and osteomyelitis imaging
Is TLX a Good Stock to Buy?
UQS Score rates TLX as Below Average overall, reflecting a mixed profile where exceptional growth momentum is offset by meaningful quality and risk concerns.
The Growth pillar stands out as TLX's clearest strength, consistent with a company that has moved from early commercialization to expanding revenue across multiple geographies. The Moat pillar registers as Neutral, acknowledging the specialized nature of radiopharmaceuticals and the regulatory barriers that protect approved products.
The Quality and Risk pillars both register as Weak, pointing to profitability pressures typical of pipeline-heavy biotech companies and elevated financial uncertainty. The Valuation pillar is Elevated, suggesting the market has already priced in considerable optimism.
Pro members can view the complete pillar breakdown and underlying financial metrics to form a more complete picture of TLX's risk-reward profile. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TLX pay dividends?
No — Telix Pharmaceuticals Limited does not currently pay a dividend.
Telix Pharmaceuticals does not currently pay a dividend. For a commercial-stage biopharmaceutical company with an active pipeline, this is typical — available capital is directed toward clinical trials, regulatory submissions, and geographic expansion rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does TLX report earnings?
Telix Pharmaceuticals reports financial results on a regular cadence, consistent with its dual listing obligations in Australia and the United States.
Revenue growth has been a defining theme for Telix in recent periods, driven primarily by Illuccix commercial uptake. However, heavy investment in pipeline development continues to weigh on profitability, reflecting the cost structure of a company still scaling its operations.
For the most recent results and upcoming reporting dates, visit Telix Pharmaceuticals' official investor relations page.
TLX Price History
-38.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Telix Pharmaceuticals Limited?
Based on Telix Pharmaceuticals Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TLX Long-term Outlook
The fundamental outlook for TLX is shaped by the tension between a Strong Growth profile and Weak Quality and Risk scores. The pipeline breadth across multiple cancer indications offers meaningful long-term optionality, but the path to sustained profitability remains uncertain. An Elevated Valuation pillar suggests that near-term execution must meet high expectations already embedded in the share price.
Growth drivers
- Continued commercial expansion of Illuccix across new geographies and clinical settings
- Pipeline progression in kidney, brain, and prostate cancer therapeutic candidates
- Growing global adoption of radiopharmaceuticals as a cancer treatment modality
Key risks
- Clinical trial failures or regulatory setbacks across the broad pipeline
- Sustained cash consumption before pipeline assets reach profitability
- Elevated valuation leaving limited margin of safety if growth disappoints
TLX vs Peers
Telix operates in a competitive specialty biopharmaceutical landscape alongside other mid-sized companies focused on rare and serious diseases.
Edgewise focuses on precision muscle biology for cardiac and skeletal muscle diseases, a distinct therapeutic area from Telix's radiopharmaceutical oncology focus.
Dianthus targets complement-mediated rare diseases through antibody therapies, contrasting with Telix's nuclear medicine and targeted radiation approach.
Travere concentrates on rare kidney and metabolic diseases, sharing some disease-area overlap with Telix's renal cancer pipeline but using entirely different treatment modalities.
Frequently Asked Questions
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals develops and commercializes radiopharmaceuticals — medicines that combine radioactive isotopes with targeting molecules to image or treat cancers. Its commercial product Illuccix is used for prostate cancer imaging, while its pipeline spans kidney, brain, and soft tissue cancers.
Does TLX pay dividends?
No, Telix Pharmaceuticals does not currently pay a dividend. The company reinvests available capital into clinical development and geographic expansion, which is standard practice for commercial-stage biopharmaceutical companies still scaling their business.
When does TLX report earnings?
Telix reports financial results on a regular schedule consistent with its Australian and US listing obligations. For exact upcoming reporting dates, check the investor relations section of the Telix Pharmaceuticals website directly.
Is TLX a good stock to buy?
The UQS Score rates TLX as Below Average overall. While the Growth pillar is Strong, the Quality and Risk pillars are both Weak and the Valuation pillar is Elevated. Investors should weigh the pipeline potential against meaningful execution and financial risk before forming a view.
Is TLX overvalued?
The UQS Valuation pillar for TLX is rated Elevated, indicating the current market price reflects a high degree of optimism about future growth. This does not guarantee the stock will decline, but it does suggest limited margin of safety if pipeline milestones are delayed or missed.
How does TLX compare to its competitors?
Telix is differentiated by its focus on radiopharmaceuticals — a specialized nuclear medicine approach to cancer — rather than conventional biologics or small molecules. Peers like Edgewise, Dianthus, and Travere operate in distinct therapeutic areas and use different treatment modalities, making direct comparison complex.
What is TLX's market cap bracket?
Telix Pharmaceuticals is classified as a mid-cap company. This places it in a bracket where commercial traction is established but the company has not yet reached the scale of large-cap pharmaceutical peers.
Who founded Telix Pharmaceuticals?
Telix Pharmaceuticals was founded in 2015. Founding and leadership history is publicly available through the company's official website and regulatory filings for those seeking detailed background on the founding team.
Is TLX a long-term quality investment?
From a long-term quality perspective, TLX's Strong Growth pillar is encouraging, but the Weak Quality and Risk scores highlight that the business has not yet demonstrated the financial durability typically associated with high-quality long-term holdings. The pipeline breadth adds optionality but also uncertainty.
What is the main competitive advantage of Telix Pharmaceuticals?
Telix's primary differentiation lies in its radiopharmaceutical platform — a technically complex field with high regulatory barriers to entry. Having an approved commercial product in Illuccix provides a revenue base that many pipeline-stage peers lack, while its multi-indication pipeline extends the potential addressable market.
What sector does TLX belong to?
TLX belongs to the Healthcare sector, specifically within the biopharmaceutical and nuclear medicine subsegment. Radiopharmaceuticals represent a growing niche within oncology, attracting increasing attention from both investors and larger pharmaceutical companies.
Is TLX a growth stock or value stock?
Based on its UQS profile, TLX leans firmly toward the growth category — the Growth pillar is rated Strong while the Valuation pillar is Elevated, a combination typical of companies where investors are paying a premium for future revenue potential rather than current earnings.
Unlock the Full TLX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics driving each pillar
- ✓Compare TLX against sector peers on quality and risk
- ✓Track pillar changes as new financial data is released
- ✓Screen for stocks with stronger Quality and Risk profiles
Pro Analysis
TLX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 41.8 | 17.4 | 46.0 | 85.0 | 19.2 | 40.6 | +0.1 |
| May 21, 2026 | 41.7 | 17.4 | 46.0 | 85.0 | 19.2 | 40.1 | 0.0 |
| May 14, 2026 | 41.7 | 17.4 | 46.0 | 85.0 | 19.2 | 39.9 | 0.0 |
| May 11, 2026 | 41.7 | 17.4 | 46.0 | 85.0 | 19.2 | 39.7 | -1.1 |
| May 8, 2026 | 42.8 | 2.5 | 46.0 | 85.0 | 36.9 | 54.3 | +1.1 |
| May 7, 2026 | 41.7 | 17.4 | 46.0 | 85.0 | 19.2 | 39.6 | +0.1 |
| May 3, 2026 | 41.6 | 17.4 | 46.0 | 85.0 | 19.2 | 39.5 | -0.1 |
| Apr 26, 2026 | 41.7 | 17.4 | 46.0 | 85.0 | 19.2 | 39.9 | 0.0 |
| Apr 19, 2026 | 41.7 | 17.4 | 46.0 | 85.0 | 19.2 | 39.7 | +0.1 |
| Apr 18, 2026 | 41.6 | 17.4 | 46.0 | 85.0 | 19.2 | 39.4 | -2.1 |
TLX — Pillar Breakdown
Quality
— 17.4/100 (25%)Telix Pharmaceuticals Limited currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.0/100 (20%)Telix Pharmaceuticals Limited is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 19.2/100 (15%)Telix Pharmaceuticals Limited presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 40.6/100 (15%)Telix Pharmaceuticals Limited has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Telix Pharmaceuticals Limited possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TLX.
Score Composition
Financial Data
More Stock Analysis
How is the TLX UQS Score Calculated?
The UQS (Unified Quality Score) for Telix Pharmaceuticals Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Telix Pharmaceuticals Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Telix Pharmaceuticals Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.